Solventum has appointed Heather Knight as chief commercial officer, effective November 10, 2025, as part of a leadership shift that includes the departure of Chris Barry.
Solventum has appointed Heather Knight as chief commercial officer, effective November 10, 2025. In this newly created role, Knight will oversee global commercial and R&D operations across the MedSurg, Dental Solutions, and Health Information Systems segments. She will report directly to CEO Bryan Hanson.
READ MORE: Industry Insider: After 3M Separation, Solventum Targets Digital Integration in Ortho
Knight brings more than 30 years of experience in the MedTech industry. Most recently, she served as chief operating officer at Baxter International, where she led global sales across three business segments as well as R&D, supply chain, and medical and regulatory affairs. She has also held leadership roles at Medtronic, Covidien, Tyco Healthcare, and Kendall, and currently serves on the Board of Directors of Waters Corporation.
“Heather’s appointment to the new role of chief commercial officer reflects Solventum’s commitment to building a high-performing organization and progress to becoming a leading global MedTech company,” said Hanson. “By aligning our go-to-market strategy under one leader, we will enhance our ability to leverage the size and scale of Solventum, driving more coordinated execution and profitable growth.”
“I am thrilled to join Solventum at this pivotal time in the execution of the company’s multi-year strategic plan,” said Knight.
As part of the leadership change, Chris Barry, executive vice president and group president of MedSurg, will depart Solventum on December 31, 2025. Hanson thanked Barry for his leadership and confirmed he will remain through year-end to support the transition.
Solventum said this change does not affect its financial guidance.
Photo: ID 240979730 © Nastassia Samal | Dreamstime.com
